PT - JOURNAL ARTICLE AU - Simons, Lacy M. AU - Lorenzo-Redondo, Ramon AU - Gibson, Meg AU - Kinch, Sarah L. AU - Vandervaart, Jacob P. AU - Reiser, Nina L. AU - Eren, Mesut AU - Lux, Elizabeth AU - McNally, Elizabeth M. AU - Tambur, Anat R. AU - Vaughan, Douglas E. AU - Bachta, Kelly E. R. AU - Demonbreun, Alexis R. AU - Satchell, Karla J. F. AU - Achenbach, Chad J. AU - Ozer, Egon A. AU - Ison, Michael G. AU - Hultquist, Judd F. TI - Assessment and Modeling of COVID-19 Outcomes in a Longitudinal Cohort of Hospitalized Adults AID - 10.1101/2021.07.02.21259665 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.02.21259665 4099 - http://medrxiv.org/content/early/2021/07/05/2021.07.02.21259665.short 4100 - http://medrxiv.org/content/early/2021/07/05/2021.07.02.21259665.full AB - Background While several demographic and clinical correlates of Coronavirus Disease 2019 (COVID-19) outcome have been identified, they remain imprecise tools for clinical management of disease. Furthermore, there are limited data on how these factors are associated with virological and immunological parameters over time.Methods and Findings Nasopharyngeal swabs and blood samples were longitudinally collected from a cohort of 58 hospitalized adults with COVID-19 in Chicago, Illinois between March 27 and June 9, 2020. Samples were assessed for SARS-CoV-2 viral load, viral genotype, viral diversity, and antibody titer. Demographic and clinical information, including patient blood tests and several composite measures of disease severity, were extracted from electronic health records. All parameters were assessed for association with three patient outcome groups: discharge without intensive care unit (ICU) admission (n = 23), discharge with ICU admission (n = 29), and COVID-19 related death (n = 6). Higher age, male sex, and higher body mass index (BMI) were significantly associated with ICU admission. At hospital admission, higher 4C Mortality scores and lactate dehydrogenase (LDH) levels were likewise associated with ICU admission. Longitudinal trends in Deterioration Index (DI) score, Modified Early Warning Score (MEWS), and serum neutrophil count were also associated with ICU admission, though only the retrospectively calculated median DI score was predictive of death. While viral load and genotype were not significantly associated with outcome in this study, viral load did correlate positively with C-reactive protein levels and negatively with D-dimer, lymphocyte count, and antibody titer. Intra-host viral genetic diversity resulted in changes in viral genotype in some participants over time, though intra-host evolution was not associated with outcome. A stepwise-generated multivariable model including BMI, lymphocyte count at admission, and neutrophil count at admission was sufficient to predict outcome with a 0.82 accuracy rate in this cohort.Conclusions These studies suggest that COVID-19 disease severity and poor outcomes among hospitalized patients are likely driven by dysfunctional host responses to infection and underlying co-morbid conditions rather than SARS-CoV-2 viral loads. Several parameters, including 4C mortality score, LDH levels, and DI score, were ultimately predictive of participant outcome and warrant further exploration in larger cohort studies for use in clinical management and risk assessment. Finally, the prevalence of intra-host diversity and viral evolution in hospitalized patients suggests a mechanism for population-level change, further emphasizing the need for effective antivirals to suppress viral replication and to avoid the emergence of new variants.Competing Interest StatementM.G.I. has received research support, paid to Northwestern University, from AiCuris, GlaxoSmithKline Janssen and Shire. M.G.I. is a paid consultant for Adagio, AlloVir, Celltrion, Cidara, Genentech, Roche, Janssen, Shionogi, Takeda, Viracor Eurofins. M.G.I. is a paid member of the data and safety monitoring board (DSMBs) from CSL Berhring, Janssen, Merck, SAB Biotherapeutics, Sequiris, and Takeda. K.J.F.S. has significant interest in Situ Biosciences, LLC, a contract research organization that conducts antimicrobial testing including coronaviruses. This project has no overlap with the interest of the company. All other authors declare no conflicts of interest.Funding StatementThis research was supported in part through the computational resources and staff contributions provided for the Quest high performance computing facility at Northwestern University, which is jointly supported by the Office of the Provost, the Office for Research, and Northwestern University Information Technology. Sample collection was supported by a COVID-19 pilot grant from the Northwestern University Clinical and Translational Science Institute (NUCATS, NIH grant UL1 TR001422). Additional funding for this work was provided by: a Northwestern Institute for Global Health Catalyzer Research Fund award (R.L.R.); a Dixon Translational Research Grant made possible by the generous support of the Dixon Family Foundation (E.A.O., J.F.H.); a CTSA supplement to NCATS UL1 TR002389 (J.F.H., E.A.O., R.L.R.); a supplement to the Northwestern University Cancer Center P30 CA060553 (J.F.H., K.E.R.B., K.J.F.S.); the Center for Structural Genomics of Infectious Diseases at Northwestern University (NIH/NIAID Contract # HHSN272201700060C, K.J.F.S.), the Gilead Sciences Research Scholars Program in HIV (J.F.H.); the NIH-supported Third Coast CFAR P30 AI117943 (R.L.R., J.F.H.); NIH grant U19 AI135964 (E.A.O.); NIH grant 3UL1 TR001422-06S4 (E.M.M. and A.R.D.); through a generous contribution from the Walder Foundation (J.F.H., E.A.O., R.L.R.); and through a generous gift from Dr. Andrew Senyei and Noni Senyei (E.M.M. and A.R.D.). The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Northwestern IRB office.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be available as supplemental material; sequencing data is available on GSAID.